Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)
 
 • Company Description   
BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

Number of Employees: 80

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.00 Daily Weekly Monthly
20 Day Moving Average: 284,404 shares
Shares Outstanding: 6.06 (millions)
Market Capitalization: $12.11 (millions)
Beta: 0.04
52 Week High: $21.92
52 Week Low: $1.17
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.99% 8.76%
12 Week 14.94% -3.32%
Year To Date -66.57% -68.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
555 LONG WHARF DRIVE
-
NEW HAVEN,CT 06511
USA
ph: 475-238-6837
fax: -
ekopp@bioxceltherapeutics.com http://www.bioxceltherapeutics.com
 
 • General Corporate Information   
Officers
Vimal Mehta - Chief Executive Officer; President; and Director
Peter Mueller - Chairman of the Board of Directors
Richard Steinhart - Senior Vice President and Chief Financial Officer
June Bray - Director
Sandeep Laumas - Director

Peer Information
BioXcel Therapeutics, Inc. (CORR.)
BioXcel Therapeutics, Inc. (RSPI)
BioXcel Therapeutics, Inc. (CGXP)
BioXcel Therapeutics, Inc. (BGEN)
BioXcel Therapeutics, Inc. (GTBP)
BioXcel Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09075P204
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 6.06
Most Recent Split Date: 2.00 (0.06:1)
Beta: 0.04
Market Capitalization: $12.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.57 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-8.60 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 33.67% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 6.54
EPS Growth
vs. Year Ago Period: 89.22%
vs. Previous Quarter: 57.98%
Sales Growth
vs. Year Ago Period: -71.13%
vs. Previous Quarter: -54.10%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -83.80
12/31/24 - -101.45
Current Ratio
06/30/25 - -
03/31/25 - 1.48
12/31/24 - 1.68
Quick Ratio
06/30/25 - -
03/31/25 - 1.45
12/31/24 - 1.65
Operating Margin
06/30/25 - -
03/31/25 - -2,163.18
12/31/24 - -2,630.14
Net Margin
06/30/25 - -
03/31/25 - -2,163.18
12/31/24 - -2,630.14
Pre-Tax Margin
06/30/25 - -
03/31/25 - -2,163.18
12/31/24 - -2,630.14
Book Value
06/30/25 - -
03/31/25 - -16.44
12/31/24 - -30.01
Inventory Turnover
06/30/25 - -
03/31/25 - 1.50
12/31/24 - 1.17
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©